210 results about "Aggresome" patented technology

The invention discloses a chimera for degrading a CARD structural domain protein aggregate and application of the chimera. The chimera is prepared from light-operated targeting protein and light-operated degradation protein, the light-operated targeting protein is sequentially connected by an MAVS CARD structural domain, a flexible connecting peptide and a photosensitive protein pMag; the light-controlled degradation protein is sequentially connected by a photosensitive protein nMag, a flexible connecting peptide and an RING structural domain of TRIM21. According to the application, a light-operated activated CARD-RING chimera is constructed, and when the CARTAC generates toxic and side effects or in cells with RIG-I / MDA5 signal channels abnormally activated, the activity of the CARTAC can be effectively controlled or autoimmune diseases caused by RIG-I / MDA5 abnormity can be inhibited.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides peptides, compositions, adsorbents, and related methods, capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from samples during the production and purification of adenovirus.

The invention belongs to the technical field of enzyme engineering and gene engineering, and particularly relates to a recombinant immobilized enzyme, an expression gene thereof and application of the recombinant immobilized enzyme in production of macrocyclodextrin. According to the preparation method, SpyTag and SpyCatcher peptides are fused to the N end of isoamylase and the N end of 4-alpha-glucanotransferase respectively, the 4-alpha-glucanotransferase modified by the SpyTag and the isoamylase modified by the SpyCatcher are obtained, and after spontaneous isopeptide bonds are formed between the SpyTag and the SpyCatcher, the self-assembled macrocyclodextrin production enzyme cluster is obtained. The obtained macrocyclodextrin production enzyme cluster forms an enzyme aggregate with a three-dimensional structure under the traditional glutaraldehyde-mediated catalytic action, namely the recombinant immobilized enzyme. The recombinant immobilized enzyme disclosed by the invention can be repeatedly utilized, is simple and convenient to operate, is easy to separate a converted product, and can be applied to industrial production of the macrocyclodextrin.

The invention relates to anti-TDP-43 binding molecules and uses thereof. The present invention is in the field of trans-activation responsive DNA binding proteins (TARDB or also referred to as TDP-43) having a molecular weight of 43 kDa. The present invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The present invention provides means and methods for diagnosing, preventing, ameliorating and / or treating diseases, disorders and / or abnormalities associated with TDP-43 aggregates, including, but not limited to, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE), and edge-dominant age-related TDP-43 encephalopathy (LATE).

The invention discloses a full-value protein biological feed production method, and relates to the technical field of protein feed production, the production method comprises the following steps: double-strain co-fermentation: cooling fermentable syrup to 38-42 DEG C, adjusting the pH value to 6.5-7.0, inoculating a mixed strain of Thermoactinomyces vulgaris and Candida utilis, fermenting for 18-24 hours under the condition that the dissolved oxygen is maintained to be 30-60%, and carrying out double-strain co-fermentation; in the process, the pH, dissolved oxygen and temperature are monitored in real time by an on-line sensor controlled by a PLC (Programmable Logic Controller), and materials are automatically supplemented; and membrane separation and concentration: enabling the fermentation liquor to pass through a PVDF (Polyvinylidene Fluoride) ultrafiltration membrane with the molecular weight cutoff of 10kDa-30kDa, and intercepting thalli and protein aggregates by a membrane concentration multiple of 5-10 to obtain a membrane concentrated solution with the protein concentration of more than or equal to 50g / L. According to the method, agricultural waste is efficiently converted into complete protein through double-bacterium synergistic fermentation, the problems that traditional single-bacterium fermentation is low in yield and unbalanced in nutrition are solved, and the protein yield is increased.

The present disclosure provides materials and methods related to the purification of a biologic from a biological fluid. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.

The present disclosure relates generally to compositions, systems, and methods for lysing blood samples comprising an infectious agent, for example a bacteria, or a fungus, while maintaining viability of the infectious agent for subsequent characterization, for example phenotyping or genotyping. A lysing composition may include one or more surfactants, such as one or more detergents. A lysing composition may include lysing agent including one or more salts. A lysing composition may include one or more enzymes to break down one or more lyses byproducts, such as nucleic acids and / or protein aggregates.

Provided is a polypeptide capable of dissolving protein aggregates. Also provided is a method of treating a phase separation associated diseases, such as phase separation associated visual disorders (e.g., cataracts) using the polypeptide provided herein.

Novel and useful compounds, such as 2,4-dihydropyrazolo[3',4':4,5]pyrano[2,3-b]pyridines, are disclosed herein. Such compounds may be employed in various treatments, alleviation, or prevention of a group of disorders, such as disorders associated with Tau (tubulin associated unit) protein aggregates, such as neurofibrillary tangles (NFTs), such as Alzheimer's disease (AD).

The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein which aggregates pathologically in neurodegenerative disease, such as tau protein, and (ii) a second portion comprising a RING-type E3 ubiquitin ligase, a component of a RING-type E3 ubiquitin ligase complex, or a domain of either. These fusion proteins have utility in selectively or preferentially targeting pathogenic protein aggregates for degradation.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).

The technical problem of the present disclosure is to provide: a composition for promoting the decomposition of protein aggregates; and a pharmaceutical composition for preventing or treating neurodegenerative diseases associated with the formation of protein aggregates. The technical problem is solved by a compound represented by general formula (I).

This invention provides a ready-to-drink milk tea based on a ternary complex stabilized with κ-casein genotype and its preparation method, belonging to the field of dairy processing technology. It includes a ternary complex of casein micelles containing AA genotype κ-casein, epigallocatechin gallate, and fructose. The preparation of the ready-to-drink milk tea includes the following steps: S1: raw material screening and pretreatment; S2: preparation of the ternary complex; S3: blending and processing of the ready-to-drink milk tea. By screening AA genotype κ-casein raw milk and using a specific sequence of first compounding EGCG and then grafting fructose, a casein micelle-EGCG-fructose ternary complex with uniform structure and controllable particle size is constructed. Fructose is further grafted onto the surface of the complex through glycosylation, effectively masking the excessive binding sites of proteins and polyphenols, significantly inhibiting the formation of insoluble aggregates, thereby maintaining excellent colloidal stability of the product during its shelf life.

A method for determining the presence of soluble, misfolded protein in or on the eye of a subject is described. The method includes contacting the eye of the subject with a monomeric protein to form an incubation mixture; incubating the incubation mixture to form a misfolded protein aggregate from the monomeric protein; and determining if a detectable amount of misfolded and / or aggregated protein is present in or on the eye; wherein detection of misfolded and / or aggregated protein indicates the presence of soluble, misfolded protein in the eye. Use of the method for diagnosing disease associated with protein misfolding in a subject is also described.

An object of the present invention is to provide a cell aggregate-inducing peptide, a cell aggregate-forming agent containing the same, and a method for forming a cell aggregate using the same.SOLUTION: A cell aggregate-inducing peptide represented by General Formula (1), having hydroxypipecolic acid and lysine as constituent repeating units. (HPA-Lys) n. (1) [In the general formula (1), HPA represents hydroxypipecolic acid, Lys represents lysine, and n is an integer of 4 or more and 30 or less.]. ] SELECTED DRAWING: None

The present invention discloses a method for monitoring the amyloid fibrillization process of lysozyme based on cluster luminescence. The method utilizes the property that lysozyme itself can emit fluorescence in an aggregated state, and the intensity of the fluorescence changes with the change of the aggregation state of lysozyme, thereby achieving the purpose of monitoring the amyloid fibrillization process of lysozyme. The method only needs to perform fluorescence detection on the fluorescence of the protein solution that can form amyloid fiber aggregates, without the introduction of exogenous fluorescent probes. The method is simple and has lower cost. The method can fully present the overall process of amyloid fibrillization and has the advantage of high sensitivity, especially high sensitivity to the early stages of amyloid fibrillization.

This invention discloses a method for preparing a secondary antibody and its application, belonging to the fields of biomedicine and bioengineering technology. The invention specifically designs an efficient multidimensional chromatographic purification strategy, sequentially passing the serum to be purified through four chromatographic columns: affinity capture (recovering IgG target molecules and removing most plasma protein impurities); antigen affinity enrichment (further enriching antibody subpopulations with high affinity and specificity to the target antigen, reducing the coexistence of non-specific subpopulations); tandem cross-adsorption (removing antibody subpopulations that cross-react to non-target species and reducing potential non-specific binding); and size exclusion / gel filtration (removing high molecular weight aggregates and low molecular weight residues, and achieving final buffer replacement and sample homogenization). The secondary antibody prepared by this invention exhibits significantly better sensitivity, specificity, and batch-to-batch consistency than existing technologies, with sensitivity improved by approximately 57% and specificity greatly enhanced compared to conventional techniques.

The invention relates to a method of detecting cancer in a subject based on the level of p53 protein aggregates in a body fluid sample from the subject. The invention also relates to corresponding methods of determining the risk of cancer in a subject, monitoring the progression or onset of cancer, and / or determining the efficacy of a therapeutic intervention for treating cancer in a subject. The invention further relates to kits for use said methods.

The invention belongs to the technical field of antibody purification, and relates to a method for removing impurities in a sample containing a trispecific antibody. According to the method provided by the invention, impurities, especially aggregates and fragments, can be well removed, and the purity detected by molecular exclusion chromatography-high performance liquid chromatography (SEC-HPLC) is increased from about 74% to 98% or above; the purity detected by non-reduction method lauryl sodium sulfate capillary electrophoresis (NR-CE-SDS) is improved from about 76% to 93% or above. Besides, the method provided by the invention can control the content of host cell protein at a lower level, greatly improves the quality of a tri-specific antibody product, and has the advantages of stable process and easiness in large-scale production.

The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).

Disclosed are compositions and methods for treating Alzheimer's disease or for use in treating Alzheimer's disease. Also disclosed are compositions and methods for treating or for use in treating a neurodegenerative disorder characterized by the presence of tau protein aggregates. Furthermore, disclosed are compositions and methods for reducing tau protein aggregates or for use in reducing tau protein aggregates.

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

The invention relates to a purification method of recombinant human serum albumin, and belongs to the technical field of protein separation and purification. A strong cation exchange filler and a weak anion exchange filler are adopted and mixed according to a specific proportion for chromatography of a mixed bed for fine purification, preferably, high-efficiency flow-through recovery is realized under the condition that the pH is 4.5-5.5, and acidic impurities and alkaline impurities are synchronously and deeply removed by the strong cation exchange filler and the weak anion exchange filler respectively; according to the present invention, the host cell protein is used as the raw material, and the composite additive system containing sodium chloride, glycine and sorbitol is matched, such that the high recovery rate of the target protein is ensured, the aggregation tendency of the target protein in the near isoelectric point environment is effectively inhibited, and the host cell protein, the endotoxin, the aggregate, the charge isomer and other impurities can be efficiently removed, the final product purity is gt; the key impurity residue is lower than the detection limit, the process robustness is high, and the method is suitable for large-scale industrial production.

The application discloses application of TRIM11 protein in preparation of a medicine for treating spinocerebellar ataxia 51. The application adopts an SCA51 specific cell model, and identifies, through a large number of screening experiments, that the TRIM11 protein has the function of significantly removing mutant THAP11 protein and aggregates thereof. Experimental data show that the mutant protein removal efficiency of the TRIM11 treatment group is significantly better than that of the control group. The application verifies the removal effect of TRIM11 on the SCA51 pathological protein from the two dimensions of protein expression level and subcellular localization through Western blotting quantitative analysis and immunofluorescence co-localization technology. The three-dimensional reconstruction image clearly shows that the mutant protein aggregates are significantly reduced. The application first establishes a complete research system from target discovery to mechanism analysis, and provides a new intervention strategy for precise treatment of SCA51.

To provide a polypeptide aggregation capacity evaluation method and a vector used in the method.SOLUTION: A polypeptide aggregation capacity evaluation method comprises measuring an amount of deoxyviolacein and / or violacein in a cell that contains a vector in which nucleotide sequences encoding a vioC protein and a vioE protein, to which a nucleotide sequence encoding a polypeptide to be evaluated is added, are included in the same vector or in different vectors.SELECTED DRAWING: None

The present application belongs to the field of biosensors, and relates to a dual-mode sensor for detecting BACE1, in particular to a dual-mode sensor for detecting BACE1 and a preparation method and application thereof. The present application first uses silver nanoparticles co-modified by luminol and short peptides as an electrochemiluminescence and electrochemical dual-mode signal unit, uses a three-dimensional aggregate formed by CB[8] induced aggregation of silver nanoparticles co-modified by luminol and short peptides P2 as a signal probe, carries out signal labeling and signal amplification, and thus improves the sensitivity of BACE1 activity detection. It is worth noting that the dual-mode sensor provides diversified analysis data for the detection of BACE1 activity, and shows high selectivity and repeatability. Compared with a single-mode sensor, the dual-mode sensor can significantly improve the analysis efficiency and accuracy, and has important scientific significance and application value.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

A method for evaluating the clogging of a filter membrane containing a protein solution includes the following steps: step a), passing the protein-containing solution through the filter membrane; step b), obtaining a cross-section of the filter membrane after step a); step c), treating the protein-containing solution before step a), or treating the filter membrane before step b), or treating the cross-section of the filter membrane after step b), using at least one staining agent specific to protein aggregates; and step d), confirming the presence of protein aggregates in the cross-section of the filter membrane.

The present invention belongs to the field of transactivation-responsive DNA binding protein with a molecular weight of 43 kDa (TARDB or also known as TDP-43). The present invention relates to TDP-43 specific binding molecules, in particular anti-TDP-43 antibodies or antigen-binding fragments or derivatives thereof and their uses. The present invention provides means and methods for diagnosing, preventing, alleviating and / or treating diseases, disorders and / or abnormalities associated with TDP-43 aggregates, including but not limited to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE) and limbic-dominant age-related TDP-43 encephalopathy (LATE).

The present invention relates to a method and system (140) for determining the presence and / or quantity of protein aggregates in a liquid sample comprising a protein. The method comprises: a) measuring ultraviolet-visible spectroscopy (UV- Vis) absorbance of the sample to obtain a UV-Vis absorbance measurement; b) measuring index of refraction (IoR) of the sample to obtain an IoR measurement; c) determining a value for the UV-Vis absorbance measurement; d) determining a value for the IoR measurement; and e) determining the presence and / or quantity of protein aggregates in the sample based on a ratio between the value for the UV-Vis absorbance measurement and the value for the IoR measurement.